Article Type

Original Study


Objectives The aim of this study was to evaluate the value of serum testosterone (total and free) and dehydroepiandrosterone (DHEA) levels in the diagnosis of patients with acute coronary syndrome (ACS) (acute non-ST-segment elevation myocardial infarction; NSTEMI) and to assess the availability of using serum androgen levels as clinical biomarkers in relation to dyslipidemia. Background Testosterone therapy may have beneficial effects on a number of risk factors of atherosclerotic ischemic heart disease. Patients and methods The study included 65 ACS patients diagnosed with acute chest pain and with positive troponin I and ECG changes (NSTEMI) and 25 normal (healthy) individuals as the control group. Serum testosterone levels have crucial roles in the diagnosis of ACS during early hours of symptoms. Results Patients with proven NSTEMI have significantly lower serum levels of androgens (total testosterone, free testosterone, and DHEA) compared with normal controls. There was a highly significant negative correlation between BMI, total cholesterol, and low density lipoprotein and free testosterone, total testosterone, and DHEA. There was also a highly significant positive correlation of the high density lipoprotein, with free testosterone, total testosterone, and DHEA. Also, serum testosterones and DHEA levels are having the same sensitivity to be decreased significantly in the blood of ACS patients. Conclusion Serum androgen levels were found to be decreased significantly in patients with NSTEMI, and this will help in early diagnosis, in making suitable therapeutic decision in few hours, and can be used in follow-up to monitor the progression of the disease.